News & Events
Prevail Therapeutics Discontinues PR006 Trial
On February 4, Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly & Co., announced the discontinuation of the PR006 “PROCLAIM” drug development program for FTD with GRN variants due…
MORE
GUIDE: A New Medicare Pilot Program Can Help Families Facing FTD
Professionals who work in the community know that dementia support services can be fragmented and difficult for families to navigate. Needed services are often provided by a variety of different…
MORE
FTD Call To Action Featured In Canadian Media
In an opinion piece published recently in the Edmonton (Alberta, CA) Journal, Naomi Mison called for reform of the bureaucracy and improvement of dementia care access in Canada. She should know: Her…
MORE
AARP Highlights What FTD Caregivers Need to Know
It’s subtle changes in speech and behavior, not memory loss, that is often the first sign of FTD, said AARP in a recent article on its website. FTD is less…
MORE
AFTD Grantee Contributes to Study on Impact of Neuropsychiatric Symptoms in PSP
A study published in the European Journal of Neurology analyzes the impact of neuropsychiatric symptoms like depression and anxiety on the quality of life of people living with progressive supranuclear…
MORE
AFTD’s Esther Kane and Volunteer Liz Zadnik Interviewed on Podcast
In a recent episode of Honestly Aging by Friends Life Care VigR®, AFTD Support & Education Director Esther Kane, and AFTD Ambassador Liz Zadnik shared a mic with host Cheryl…
MORE
The Lived FTD Experience: FTD in the Arts
Science tells us that neurodegenerative disease can sometimes reveal unexplored creative talents, and that creating art can be a useful diversion from stress and grief. For those reasons, starting in…
MORE
Brain Donation is Final Gift of 24-Year-Old Diagnosed with FTD
Brain donation can be a selfless act born of tragedy. The story of Andre Yarham has captured the attention of media outlets across the United Kingdom, highlighting both the reach of FTD into young adulthood, and the…
MORE
